Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …
Read More »
The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …
Read More »
GLP‑1 receptor agonists have transformed the way we manage type 2 diabetes and obesity—but could they also play a role in sleep apnea treatment? The intersection of GLP-1 sleep apnea benefits is gaining attention, with new evidence suggesting these therapies may offer more than just weight loss. With diabetes and …
Read More »
By Eugene Thompson Twelve years ago, at age 47 and weighing over 250 pounds, I stood at a crossroads. My life, once vibrant and full of energy, had become unrecognizable. I was constantly tired, overweight, and stuck in a cycle of poor health. All the doctors would do for me …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.